Declaration of interest
J.T. received personal fees from AstraZeneca, Janssen-Cilag, Otsuka, Bristol-Myers Squibb, Lundbeck, Organon, Eli Lilly, F. Hoffmann-La Roche, GlaxoSmithKline, Pfizer, Novartis and receives a grant from Stanley Foundation, outside the submitted work.
Behavioural and psychological symptoms of dementia are frequently treated with antipsychotics.
To determine the incidence of antipsychotic use in relation to diagnosis of Alzheimer's disease.
Cohort of all community-dwellers in Finland diagnosed with Alzheimer's disease in 2005 and matched controls. All antipsychotics dispensed between 1995 and 2009 were extracted from the Finnish National Prescription Register.
Altogether 1996/6087 (32.8%) persons with Alzheimer's disease initiated antipsychotic use. The incidence of antipsychotic use was fivefold among persons with Alzheimer's disease compared with controls, started to increase 2–3 years before diagnosis and was highest during the first 6 months after diagnosis.
A distinct increase in antipsychotic initiations occurs in the same time window as Alzheimer's disease diagnosis.
- © The Royal College of Psychiatrists 2015.